Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 7 December 2001:
Vol. 294. no. 5549, pp. 2079 - 2080
DOI: 10.1126/science.294.5549.2079
Prev | Table of Contents | Next

News Focus

PROTEOMICS:
A Proteomics Upstart Tries to Outrun the Competition

Robert F. Service

GENEVA, SWITZERLAND--By assembling an arsenal of technology--including a research lab here in the outskirts of Geneva, one under construction in New Jersey, and a possible one in Japan--GeneProt, the biggest test-bed to date in the young field of proteomics, aims to identify proteins associated with disease. The company is banking that these proteins will produce a string of lucrative drugs aimed at top killers such as cancer and heart disease. GeneProt's moves have inspired both awe and skepticism among other proteomics researchers.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)